The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

STING Pathway Targeting Therapeutics and Technologies - by Type (Agonist and Antagonist), Molecule (Cyclic Dinucleotides, Non-nucleotides, Live Biotherapeutics, Oncolytic Viruses, Synthetic Peptides and Others), Therapeutic Area (Oncological Disorders, Inflammatory Disorders, Infectious Diseases and Other Diseases), Route of Administration (Intratumoral, Intravenous, Subcutaneous, Oral and Others) and Geographies: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    September 2020

  • Pages
    328

  • View Count
    1091

Example Insights

STING-Pathway-Targeting-Therapeutics-and-Technologies-Context STING-Pathway-Targeting-Therapeutics-and-Technologies-Distribution-by-Stage STING-Pathway-Targeting-Therapeutics-and-Technologies-Pipeline STING-Pathway-Targeting-Therapeutics-and-Technologies-Start-up-Health-Indexing
STING-Pathway-Targeting-Therapeutics-and-Technologies-Big-Pharma-Initiatives STING-Pathway-Targeting-Therapeutics-and-Technologies-Publication-Analysis STING-Pathway-Targeting-Therapeutics-and-Technologies-Grant-Analysis STING-Pathway-Targeting-Therapeutics-and-Technologies-Funding-and-Investments
STING-Pathway-Targeting-Therapeutics-and-Technologies-Partnerships-and-Collaborations STING-Pathway-Targeting-Therapeutics-and-Technologies-Distribution-by-Type-of-Molecule STING-Pathway-Targeting-Therapeutics-and-Technologies-Future-Forecast  

 

Overview

In recent years, promising insights from research on the cytosolic DNA sensing (cGAS -STING) pathway has caused a lot of enthusiasm within medical science community. Basically, the STING pathway offers an alternative approach to harnessing the immune system, in order to pharmacologically treat a number of clinical conditions, including oncological and autoimmune disorders. The aforementioned therapeutic benefits can be achieved using modulators of the STING / cGAS-pathway. Over the years, a number of such modulators, capable of either activating or downregulating the STING pathway, have been developed. More than 50 experimental interventions based on this relatively novel concept are currently being developed for the treatment of oncological, autoimmune and inflammatory disorders. 

The popularity of STING pathway modulation and growing interest of drug developers in this upcoming field of therapeutics is evident in the rising volume of affiliated scientific literature (1,000+ related articles on NCBI’s PubMed portal since 2015). Moreover, capital investments worth over USD 2.6 billion have been made by various private and public sector investors to fund product development activity. In addition, there have been multiple, high value technology licensing deals in this domain, since 2015. As a result, there has been a considerable rise in number of companies taking initiatives in this field, over the past 4-5 years alone. Interestingly, several big pharma players are also actively evaluating multiple STING agonists / antagonists. It is also worth noting that molecular research into the pathogenesis of the novel SARS-CoV-2 viral strain suggests that COVID-19 may be a STING-related disorder, characterized by delayed over-secretion of IFN-β. STING, in humans, is mostly expressed in lung alveolar epithelial cells, endothelial cells, and spleen cells, which are considered crucial for COVID-19 pathogenesis. Therefore, rapid assessments of STING polymorphisms may actually be useful in identifying individuals who are at high risks of contracting a severe form of this infection. Further, a better understanding of the underlying mechanisms associated with the novel coronavirus induced STING-pathway over-activation, may enable the development of potential therapeutic candidates against COVID-19. Currently, there are no approved STING pathway-targeting drugs / therapy products in the market. However, some promising leads are anticipated to be launched over the coming decade, following which the market is projected to grow at a substantial pace.

Scope of the Report

The “STING Pathway Targeting Therapeutics and Technologies - By Type (Agonist and Antagonist), Molecule (Cyclic Dinucleotides, Non-nucleotides, Live Biotherapeutics, Oncolytic Viruses, Synthetic Peptides and Others), Therapeutic Area (Oncological Disorders, Inflammatory Disorders, Infectious Diseases and Other Diseases), Route of Administration (Intratumoral, Intravenous, Subcutaneous, Oral and Others) and Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2020-2030” report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade. This study focuses specifically on small molecule STING modulators. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater). The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players). Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints.
  • A detailed chapter highlighting various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography).
  • Elaborate profiles of key players that are engaged in the development of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, recent developments and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications and current status of development.
  • Tabulated profiles of industry players (shortlisted on the basis of the antagonist in pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, key members of the executive team and recent developments), along with descriptions of their respective drug candidates. 
  • A study on various grants that have been awarded to research institutes engaged in projects related to STING pathway, during the period 2015 - Q1 2020, based on multiple parameters, such as number of grants awarded, amount awarded, funding institute, support period, funding mechanism, type of grant application, grant activity code, most popular NIH department, type of recipient organization, regional distribution, most popular recipient organization(s), prominent project leader(s) and study section. It also includes an analysis of on grant attractiveness.
  • An analysis of big pharma players engaged in the development of therapeutics targeting STING pathway, based on several parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area(s), type of therapy and route of administration. In addition, the chapter features a benchmarking analysis of the aforementioned players. 
  • An analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of therapeutics targeting STING pathway, based on several relevant parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area, funding received, number of investors, type of funding, partnership activity, number of patents filed, grants received, and start-up health indexing. 
  • A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of STING modulator, target pathway, therapeutic area, type of publisher, leading players (in terms of number of publications), region, first author organization and key journals (in terms of number of articles published in this domain). 
  • An analysis of the partnerships that have been established in the domain, over the period 2015 - Q1 2020, covering research agreements, product / technology licensing agreements, mergers / acquisitions,  R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals. The chapter highlights analysis based on year of partnerships, type of partnership model, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of partnerships inked), and region.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies engaged in this field. The chapter highlights analysis based on the number of funding instances, amount invested, type of funding, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of funding instances), most active investor(s) (in terms of number of funding instances) and geographical region.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of STING pathway modulators. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030. The report features likely distribution of the current and forecasted opportunity across [A] type of STING modulator (agonist and antagonist), [B] type of molecule (non-nucleotides, cyclic dinucleotides, live biotherapeutics, oncolytic viruses, synthetic peptides and others) [C] therapeutic area (oncological disorders, inflammatory disorders, infectious diseases and other disorders), [D] route of administration (intratumoral, intravenous, oral, subcutaneous and others), [E] type of technology licensing payment / revenue (upfront payments and milestone payments) and [F] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of market for therapeutics targeting STING pathway and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Krzysztof Brzózka (Chris) (Chief Scientific Officer, Ryvu Therapeutics)
  • Glen N Barber (Chief Executive Officer, STINGINN)

 All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of therapeutics targeting STING pathway market and its likely evolution in the short-mid and long term.

Chapter 3 is an introductory chapter that provides details related to the STING pathway and its role in signaling. It further includes an elaborate discussion on the role of STING in oncological disorders, autoimmune diseases and antimicrobial host defense. Further, the chapter provides an overview of the compounds that can be used for activation or inhibition of the aforementioned pathway (agonists, antagonists, STING activating delivery systems and indirect STING activating therapies). In addition, it describes key variants of STING and the non-immunological functions of the pathway (cell apoptosis, autophagy, cell proliferation and others).

Chapter 4 includes detailed assessment on more than 50 therapeutics targeting STING pathway; the analysis  is based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discover, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater). The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players). Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints.

Chapter 5 highlights various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography)..

Chapter 6 features elaborate profiles of key players that are engaged in the development of agonist therapeutics targeting STING Pathways (shortlisted on the basis of phase of development of pipeline products). Each company profile includes a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications and current status of development. Further, the chapter includes tabulated profiles of industry players (shortlisted on the basis of the antagonist in pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, key members of the executive team and recent developments), along with descriptions of their respective drug candidates.

Chapter 7 provides information on the various grants that were awarded to research institutes conducting projects related to therapeutics targeting STING pathway, during the period 2015 - Q1 2020, based on multiple parameters, such as number of grants awarded, amount awarded, funding institute, support period, funding mechanism, type of grant application, grant activity code, most popular NIH department, type of recipient organization, regional distribution, most popular recipient organization(s), prominent project leader(s) and study section. It also includes an analysis of on grant attractiveness.

Chapter 8 features the detailed analysis of all the big pharma players engaged in the development of therapeutics targeting STING pathway, based on several parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area(s), type of therapy and route of administration. In addition, the chapter features a benchmarking analysis of the aforementioned players.

Chapter 9 presents an analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of therapeutics targeting STING pathway, based on several relevant parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area, funding received, number of investors, type of funding, partnership activity, number of patents filed, grants received, and start-up health indexing.

Chapter 10 presents a detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of STING modulator, target pathway, therapeutic area, type of publisher, leading players (in terms of number of publications), region , first author organization and key journals (in terms of number of articles published in this domain). 

Chapter 11 features an elaborate analysis and discussion of partnerships / collaborations that have been established in this domain, over the period 2015 - Q1 2020, covering research agreements, product / technology licensing agreements, mergers / acquisitions,  R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals. The chapter highlights analysis based on year of partnerships, type of partnership model, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of partnerships inked), and region.

Chapter 12 provides analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies engaged in this field. The chapter highlights analysis based on the number of funding instances, amount invested, type of funding, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of funding instances), most active investor(s) (in terms of number of funding instances) and geographical region.

Chapter 13 features a comprehensive market forecast, highlighting the future potential of novel technologies designed for the development of STING pathway modulators till 2030, based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] type of STING modulator (agonist and antagonist), [B] type of molecule (non-nucleotides, cyclic dinucleotides, live biotherapeutics, oncolytic viruses, synthetic peptides and others) [C] therapeutic area (oncological disorders, inflammatory disorders, infectious diseases and other disorders), [D] route of administration (intratumoral, intravenous, oral, subcutaneous and others), [E] type of technology licensing payment / revenue (upfront payments and milestone payments) and [F] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of market for therapeutics targeting STING pathway and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 14 is a collection of executive insights of the discussions that were held with various key stakeholders in this market.

Chapter 15 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Stimulator of Interferon Genes (STING) Pathway 
3.2. STING Signaling 
3.2.1. Relevance in Cancer
3.2.2. Relevance in Autoimmune Diseases
3.2.3. Relevance in Antimicrobial Host Defense

3.3. STING Pathway Modulators
3.3.1. STING Agonists
3.3.2. STING Antagonists
3.3.3. STING Activating Drug Delivery Systems
3.3.4. Indirect STING Activating Therapies
3.4. Key Variants of STING
3.5. Non-immunological Functions of the STING Pathway
3.6. Concluding Remarks

4. STING PATHWAY TARGETING THERAPEUTICS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. STING Pathway Targeting Therapeutics: Development Pipeline
4.2.1. Analysis by Type of STING Modulator
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Phase of Development
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Line of Treatment

4.3. STING Pathway Targeting Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geography
4.3.4. Most Active Players

4.4. STING Pathway Targeting Therapeutics: List of Clinical Trials
4.4.1. Analysis by Trial Recruitment Status
4.4.2. Analysis by Study Design
4.4.3. Analysis by Key Clinical Endpoints

5. STING PATHWAY TARGETING TECHNOLOGIES: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. STING Pathway Targeting Technologies: List of Technology Developers
5.2.1. Analysis by Type of Modulator
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Year of Establishment
5.2.4. Analysis by Company Size
5.2.5. Analysis by Geography

6. COMPANY PROFILES
6.1. Chapter Overview
6.2 STING Agonist Developers
6.2.1. Aduro Biotech
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Description: ADU-S100 (MIW815)
6.2.1.4. Recent Developments and Future Outlook

6.2.2. Bristol-Myers Squibb
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Description: BMS-986301
6.2.2.4. Recent Developments and Future Outlook

6.2.3. Eisai
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Description: E7766
6.2.3.4. Recent Developments and Future Outlook

6.2.4 GlaxoSmithKline
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Product Description: GSK3745417
6.2.4.4. Recent Developments and Future Outlook

6.2.5. ImmuneSensor Therapeutics
6.2.5.1. Company Overview
6.2.5.2. Product Description: IMSA101

6.2.6. Merck
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Product Description: MK-1454 and MK-2118
6.2.6.4. Recent Developments and Future Outlook

6.2.7. Noxopharm
6.2.7.1. Company Overview
6.2.7.2. Product Description: NOX66
6.2.7.3. Recent Developments and Future Outlook

6.2.8. Spring Bank Pharmaceuticals
6.2.8.1. Company Overview
6.2.8.2. Financial Information
6.2.8.3. Product Description: SB 11285
6.2.8.4. Recent Developments and Future Outlook

6.2.9. Synlogic
6.2.9.1. Company Overview
6.2.9.2. Financial Information
6.2.9.3. Product Description: SYNB1891
6.2.9.4. Recent Developments and Future Outlook

6.3. STING Antagonist Developers
6.3.1 Avammune Therapeutics
6.3.2. Curadev
6.3.3 ImmuneSensor Therapeutics
6.3.4. Nimbus Therapeutics
6.3.5. Sirenas
6.3.6. Spring Bank Pharmaceuticals
6.3.7. STINGINN
6.3.8. STipe Therapeutics

7. ACADEMIC GRANT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. STING Pathway Targeting Therapeutics: List of Academic Grants
7.3.1. Analysis by Number of Grants
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Mechanism
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Grant Activity Code
7.3.8. Analysis by Funding Institutes
7.3.9. Analysis by Type of Recipient Organization
7.3.10 Regional Distribution of Grant Recipients
7.3.11 Most Popular Recipient Organizations: Analysis by Number of Grants and Amount Invested
7.3.12. Prominent Project Leaders: Analysis by Number of Grants
7.3.13 Analysis by Support Year and Amount Awarded
7.3.14. Analysis by Study Section
7.4. Grant Attractiveness Analysis

8. STING RELATED INITIATIVES OF BIG PHARMACEUTICALS PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives Undertaken by Big Pharma Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Type of Molecule
8.3.3. Analysis by Phase of Development
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Type of Therapy
8.3.6. Analysis by Route of Administration

8.4. Benchmarking Big Pharma Players
8.4.1 Spider Web Analysis: AbbVie
8.4.2. Spider Web Analysis: Bayer
8.4.3. Spider Web Analysis: Bristol-Myers Squibb
8.4.4. Spider Web Analysis: Celgene
8.4.5. Spider Web Analysis: Eisai
8.4.6. Spider Web Analysis: Eli Lily
8.4.7. Spider Web Analysis: Genentech
8.4.8. Spider Web Analysis: GlaxoSmithKline
8.4.9. Spider Web Analysis: Merck
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: Takeda Pharmaceuticals

9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Type of Molecule
9.3.3. Analysis by Phase of Development
9.3.4 Analysis by Therapeutic Area
9.3.5. Analysis by Funding Amount
9.3.6. Analysis by Number of Investors
9.3.7. Analysis by Type of Funding
9.3.8. Analysis by Partnership Activity
9.3.9. Analysis by Other Parameters
9.3.10. Analysis by Location of Headquarters
9.3.11. Start-up Health Indexing: Roots Analysis Perspective

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. STING Pathway Targeting Therapeutics: Recent Publications
10.3.1. Analysis by Type of Publication
10.3.2. Analysis by Type of Publication and Year
10.3.3. Analysis by Study Objective
10.3.4. Analysis by Popular Keywords 
10.3.5. Analysis by Type of STING Modulator
10.3.6. Analysis by Target Pathway
10.3.7. Analysis by Therapeutic Area
10.3.8. Analysis by Type of STING Modulator and Therapeutic Area
10.3.9 Analysis by Type of Publisher
10.3.10. Leading Players: Analysis by Number of Publications
10.3.11. Leading Players: Geographical Analysis by Number of Publications
10.3.12. Analysis by First Author Organization
10.3.13. Key Journals: Analysis by Number of Publications

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. STING Pathway Targeting Therapeutics: Recent Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3 Analysis by Type of STING Modulator
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Technology Platform
11.3.6. Most Active Players: Analysis by Number of Partnerships

11.3.7. Geographical Analysis
11.3.7.1 Most Active Players: Analysis by Number of partnerships
11.3.7.2. Intercontinental and Intracontinental Agreements

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. STING Pathway Targeting Therapeutics: Recent Funding Instances
12.3.1. Analysis by Number of Funding Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Type of STING Modulator
12.3.6. Analysis by Therapeutic Area
12.3.6 Analysis by Amount Invested and Type of STING Technology Platform
12.3.7. Most Active Players: Analysis by Number of Funding Instances
12.3.8. Most Active Investors: Analysis by Number of Funding Instances
12.3.9. Geographical Analysis by Amount Invested
12.4. Concluding Remarks

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global STING Pathway Targeting Technologies Market, 2020-2030
13.3.1. STING Pathway Targeting Technologies Market by Upfront Payments, 2020-2030
13.3.2. STING Pathway Targeting Technologies Market by Milestone Payments, 2020-2030
13.3.3. STING Pathway Targeting Technologies Market: Distribution by Type of STING Modulator
13.3.3.1. STING Pathway Targeting Technologies Market for Agonist, 2020-2030
13.3.3.2. STING Pathway Targeting Technologies Market for Antagonist, 2020-2030

13.3.4. STING Pathway Targeting Technologies Market: Distribution by Therapeutic Area
13.3.4.1. STING Pathway Targeting Technologies Market for Oncological Disorders, 2020-2030
13.3.4.2. STING Pathway Targeting Technologies Market for Inflammatory Disorders, 2020-2030
13.3.4.3. STING Pathway Targeting Technologies Market for Infectious Diseases, 2020-2030
13.3.4.4. STING Pathway Targeting Technologies Market for Other Therapeutic Areas, 2020-2030

13.3.5. STING Pathway Targeting Technologies Market: Distribution by Route of Administration
13.3.5.1. STING Pathway Targeting Technologies Market for Intratumoral Route, 2020-2030
13.3.5.2. STING Pathway Targeting Technologies Market for Intravenous Route, 2020-2030
13.3.5.3. STING Pathway Targeting Technologies Market for Oral Route, 2020-2030
13.3.5.4. STING Pathway Targeting Technologies Market for Subcutaneous Route, 2020-2030
13.3.5.5. STING Pathway Targeting Technologies Market for Other Routes, 2020-2030

13.3.6. STING Pathway Targeting Technologies Market: Distribution by Type of Molecule
13.3.6.1. STING Pathway Targeting Technologies Market for Non-Nucleotide, 2020-2030
13.3.6.2. STING Pathway Targeting Technologies Market for Cyclic Dinucleotide, 2020-2030
13.3.6.3. STING Pathway Targeting Technologies Market for Live Biotherapeutics, 2020-2030
13.3.6.4. STING Pathway Targeting Technologies Market for Oncolytic Viruses, 2020-2030
13.3.6.5. STING Pathway Targeting Technologies Market for Synthetic Peptides, 2020-2030
13.3.6.6. STING Pathway Targeting Technologies Market for Other Molecules, 2020-2030

13.3.7. STING Pathway Targeting Technologies Market: Distribution by Geography
13.3.7.1. STING Pathway Targeting Technologies Market in North America, 2020-2030
13.3.7.2. STING Pathway Targeting Technologies Market in Europe, 2020-2030
13.3.7.3. STING Pathway Targeting Technologies Market in Asia-Pacific, 2020-2030

14. EXECUTIVE INSIGHTS

15. CONCLUDING REMARKS
15.1. Chapter Overview
15.2. Key Takeaways

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 STING Signaling Pathway
Figure 4.1 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator
Figure 4.2 STING Pathway Targeting Therapeutics: Distribution by Type of Molecule
Figure 4.3 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator and Type of Molecule
Figure 4.4 STING Pathway Targeting Therapeutics: Distribution by Phase of Development
Figure 4.5 STING Pathway Targeting Therapeutics: Distribution by Type of Molecule and Phase of Development
Figure 4.6 STING Pathway Targeting Therapeutics: Distribution by Therapeutic Area
Figure 4.7 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator and Target Indication(s)
Figure 4.8 STING Pathway Targeting Therapeutics: Distribution by Type of Therapy
Figure 4.9 STING Pathway Targeting Therapeutics: Distribution by Route of Administration
Figure 4.10 STING Pathway Targeting Therapeutics: Distribution by Line of Treatment
Figure 4.111 STING Pathway Targeting Therapeutics Developers: Distribution by Year of Establishment
Figure 4.12 STING Pathway Targeting Therapeutics Developers: Distribution by Company Size
Figure 4.13 STING Pathway Targeting Therapeutics Developers: Distribution by Leading Player
Figure 4.14 STING Pathway Targeting Therapeutics Developers: Distribution by Type of STING Modulator
Figure 4.15 STING Pathway Targeting Therapeutics Developers: Distribution by Type of Molecule
Figure 4.16 STING Pathway Targeting Therapeutics Developers: Analysis by Geography
Figure 4.17 Clinical Trials: Distribution by Trial Recruitment Status
Figure 4.18 Clinical Trials: Grid Analysis
Figure 4.19 Clinical Trials: Distribution by Study Design
Figure 4.20 Clinical Trials: Benchmarking of Industry Players by Number of Trials across Key Therapeutics Indications
Figure 4.21 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Figure 5.1 STING Pathway Targeting Technologies: Distribution by Type of Modulator
Figure 5.2 STING Pathway Targeting Technologies: Distribution by Type of Molecule
Figure 5.3 STING Pathway Targeting Technologies: Distribution by Year of Establishment
Figure 5.4 STING Pathway Targeting Technologies: Distribution by Company Size
Figure 5.5 STING Pathway Targeting Technologies: Distribution by Geography
Figure 6.1 Aduro Biotech: Net Revenues, FY 2015- Q1 2020 (USD Million)
Figure 6.2 Bristol-Myers Squibb: Net Revenues, FY 2015- Q1 2020 (USD Million)
Figure 6.3 Eisai: Net Revenues, FY 2015 - Q1 2020 (USD Billion)
Figure 6.4 GlaxoSmithKline: Net Revenues, FY 2015 - Q1 2020 (USD Billion)
Figure 6.5 Merck: Net Revenues, FY 2015 - Q1 2020 (USD Billion)
Figure 6.6 Spring Bank Pharmaceuticals: Net Working Capital, FY 2015 – FY 2019 (USD Million)
Figure 6.7 Synlogic: Net Revenues, FY 2016 - Q1 2020 (USD Million)
Figure 7.1 Academic Grant Analysis: Year–wise Trend
Figure 7.2 Academic Grant Analysis: Distribution by Amount Awarded (USD Million)
Figure 7.3 Academic Grant Analysis: Distribution by Administering Institute Center
Figure 7.4 Academic Grant Analysis: Distribution by Support Period
Figure 7.5 Academic Grant Analysis: Distribution by Funding Mechanism
Figure 7.6 Academic Grant Analysis: Distribution by Type of Grant Application
Figure 7.7 Academic Grant Analysis: Distribution by Activity of Grant
Figure 7.8 Academic Grant Analysis: Most Popular NIH Departments
Figure 7.9 Academic Grant Analysis: Distribution by Recipient Organization
Figure 7.10 Academic Grant Analysis: Regional Distribution by Recipient Organization
Figure 7.11 Academic Grant Analysis: Distribution by Number of Grants and Amount Awarded
Figure 7.12 Prominent Project Leaders: Distribution by Number of Grants Awarded
Figure 7.13 Prominent Project Leaders: Distribution by Amount Awarded
Figure 7.14 Academic Grant Analysis: Distribution by Support Period
Figure 7.15 Academic Grant Analysis: Distribution by Study Section
Figure 7.16 Academic Grant Analysis: Grant Attractiveness
Figure 8.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 8.2 Big Pharma Players: Heat Map Analysis of Other Pharmaceutical Companies
Figure 8.3 Big Pharma Players: Analysis by Portfolio Diversity
Figure 8.4 Big Pharma Players: Analysis by Type of Molecule
Figure 8.5 Big Pharma Players: Analysis by Phase of Development
Figure 8.6 Big Pharma Players: Analysis by Diversity of Therapeutic Areas
Figure 8.7 Big Pharma Players: Analysis by Type of Therapy
Figure 8.8 Big Pharma Players: Analysis by Route of Administration
Figure 8.9 Spider Web Analysis: AbbVie
Figure 8.10 Spider Web Analysis: Bayer
Figure 8.11 Spider Web Analysis: Bristol-Myers Squibb
Figure 8.12 Spider Web Analysis: Celgene
Figure 8.13 Spider Web Analysis: Eisai
Figure 8.14 Spider Web Analysis: Eli Lily
Figure 8.15 Spider Web Analysis: Genentech
Figure 8.16 Spider Web Analysis: GlaxoSmithKline
Figure 8.17 Spider Web Analysis: Merck
Figure 8.18 Spider Web Analysis: Novartis
Figure 8.19 Spider Web Analysis: Novo Nordisk
Figure 8.20 Spider Web Analysis: Pfizer
Figure 8.21 Spider Web Analysis: Roche
Figure 8.22 Spider Web Analysis: Takeda Pharmaceuticals
Figure 9.1. Benchmark Analysis of Start-ups: Distribution by Portfolio Diversity
Figure 9.2 Benchmark Analysis of Start-ups: Distribution by Type of Molecule
Figure 9.3 Benchmark Analysis of Start-ups: Distribution by Phase of Development
Figure 9.4 Benchmark Analysis of Start-ups: Distribution by Therapeutic Area
Figure 9.5 Benchmark Analysis of Start-ups: Distribution by Location
Figure 9.6 Benchmark Analysis of Start-ups: Distribution by Funding Amount
Figure 9.7 Benchmark Analysis of Start-ups: Distribution by Number of Investors
Figure 9.8 Benchmark Analysis of Start-ups: Distribution by Progression in Funding
Figure 9.9 Benchmark Analysis of Start-ups: Distribution by Partnership Activity
Figure 9.10 Benchmark Analysis of Start-ups: Distribution by Patent Portfolio
Figure 9.11 Benchmark Analysis of Start-ups: Distribution by Grant Portfolio
Figure 9.12 Benchmark Analysis of Start-ups: Distribution by Number of Publications
Figure 9.13 Start-up Health Indexing: Roots Analysis Perspective
Figure 10.1 Publication Analysis: Cumulative Year-wise Trend, 2015 - Q1 2020
Figure 10.2 Recent Publications: Distribution by Type of Publication
Figure 10.3 Recent Publications: Distribution by Year and Type of Publication
Figure 10.4 Recent Publications: Distribution by Study Objective
Figure 10.5 Recent Publications: Distribution by Emerging Focus Area
Figure 10.6 Recent Publications: Distribution by Type of Molecule
Figure 10.7 Recent Publications: Distribution by Target Pathway
Figure 10.8 Recent Publications: Distribution by Therapeutic Area
Figure 10.9 Recent Publications: Distribution by Type of Molecule and Therapeutic Area
Figure 10.10 Recent Publications: Distribution by Type of Publisher
Figure 10.11 Most Active Players: Distribution by Number of Publications
Figure 10.12 Leading Players: Geographical Distribution by Number of Publications
Figure 10.13 Leading Players: Distribution by First Author Organization
Figure 10.14 Key Journals: Distribution by Number of Publications
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015 - Q1 2020
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Type of STING Modulator
Figure 11.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.6 Partnerships and Collaborations: Year-wise Trend by Type of Therapeutic Area
Figure 11.7 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Figure 11.8 Partnership and Collaborations: Distribution by Technology Platform
Figure 11.9 Most Active Players: Distribution by Number of Partnerships
Figure 11.10 Most Active Players: Geographical Distribution by Number of Partnerships
Figure 11.11 Partnerships and Collaborations: Intercontinental and Intracontinental Distributions
Figure 12.1 Funding and Investments: Distribution by Year of Establishment and Type of Funding, 2015 - Q1 2020
Figure 12.2 Funding and Investments: Distribution by Type of STING Modulator and Type of Funding
Figure 12.3 Funding and Investments: Cumulative Year-wise Trend, 2015 - Q1 2020
Figure 12.4 Funding and Investments: Cumulative Amount Invested by Year, 2015 - Q1 2020 (USD Million)
Figure 12.5 Funding and Investments: Distribution by Type of Funding
Figure 12.6 Funding and Investments: Year-wise Trend of Amount Invested, 2015 - Q1 2020 (USD Million)
Figure 12.7 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 12.8 Funding and Investments: Summary of Investments, 2015 - Q1 2020 (USD Million)
Figure 12.9 Funding and Investments: Distribution by Type of Modulator
Figure 12.10 Funding and Investments: Distribution by Therapeutic Area
Figure 12.12 Funding and Investments: Distribution of Amount Invested by Therapeutic Area, 2015 - Q1 2020
Figure 12.13 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Figure 12.14 Most Active Players: Distribution by Number of Instances
Figure 12.15 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 12.16 Most Active Investors: Distribution by Amount Invested (USD Million)
Figure 12.17 Funding and Investment: Geographical Distribution by Amount Invested (USD Million)
Figure 12.18 Funding and Investment: Summary
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 STING Pathway Targeting Therapeutics: Payment Structure
Figure 13.3 Global STING Pathway Targeting Technologies Market, 2020-2030 (USD Million)
Figure 13.4 STING Pathway Targeting Technologies Market by Upfront Payments, 2020-2030 (USD Million)
Figure 13.5 STING Pathway Targeting Technologies Market by Milestone Payments, 2020-2030 (USD Million)
Figure 13.6 STING Pathway Targeting Technologies Market for Agonists, 2020-2030 (USD Million)
Figure 13.7 STING Pathway Targeting Technologies Market for Antagonists, 2020-2030 (USD Million)
Figure 13.8 STING Pathway Targeting Technologies Market for Oncological Disorders, 2020-2030 (USD Million)
Figure 13.9 STING Pathway Targeting Technologies Market for Inflammatory Disorders, 2020-2030 (USD Million)
Figure 13.10 STING Pathway Targeting Technologies Market for Infectious Diseases, 2020-2030 (USD Million)
Figure 13.11 STING Pathway Targeting Technologies Market for Other Therapeutic Areas, 2020-2030 (USD Million)
Figure 13.12 STING Pathway Targeting Technologies Market for Intratumoral Route, 2020-2030 (USD Million)
Figure 13.13 STING Pathway Targeting Technologies Market for Intravenous Route, 2020-2030 (USD Million)
Figure 13.14 STING Pathway Targeting Technologies Market for Oral Route, 2020-2030 (USD Million)
Figure 13.15 STING Pathway Targeting Technologies Market for Subcutaneous Route, 2020-2030 (USD Million)
Figure 13.16 STING Pathway Targeting Technologies Market for Other Routes, 2020-2030 (USD Million)
Figure 13.17 STING Pathway Targeting Technologies Market for Non-nucleotides, 2020-2030 (USD Million)
Figure 13.18 STING Pathway Targeting Technologies Market for Cyclic Dinucleotides, 2020-2030 (USD Million)
Figure 13.19 STING Pathway Targeting Technologies Market for Live Biotherapeutics, 2020-2030 (USD Million)
Figure 13.20 STING Pathway Targeting Technologies Market for Oncolytic Viruses, 2020-2030 (USD Million)
Figure 13.21 STING Pathway Targeting Technologies Market for Synthetic Peptides, 2020-2030 (USD Million)
Figure 13.22 STING Pathway Targeting Technologies Market for Other Molecules, 2020-2030 (USD Million)
Figure 13.23 STING Pathway Targeting Technologies Market in North America, 2020-2030 (USD Million)
Figure 13.24 STING Pathway Targeting Technologies Market in Europe, 2020-2030 (USD Million)
Figure 13.25 STING Pathway Targeting Technologies Market in Asia-Pacific, 2020-2030 (USD Million)

List Of Tables

Table 3.1 Role of DNA and RNA viruses in STING Signaling
Table 4.1 STING Pathway Targeting Therapeutics: Development Pipeline
Table 4.2 STING Pathway Targeting Therapeutics: Information on Phase of Development and Target Indication
Table 4.3 STING Pathway Targeting Therapeutics: Information on Type of Therapy and Route of Administration
Table 4.4 STING Pathway Targeting Therapeutics: Developer Landscape
Table 4.5 STING Pathway Targeting Therapeutics: List of Clinical Trials
Table 5.1 STING Pathway Targeting Technologies: List of Technology Developers
Table 6.1 Aduro Biotech: Key Highlights
Table 6.2 Aduro Biotech: Key Characteristics of ADU-S100 (MIW815)
Table 6.3 Aduro Biotech: Recent Developments and Future Outlook
Table 6.4 Bristol-Myers Squibb: Key Highlights
Table 6.5 Bristol-Myers Squibb: Key Characteristics of BMS-986301
Table 6.6 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 6.7 Eisai: Key Highlights
Table 6.8 Eisai: Key Characteristics of E7766
Table 6.9 Eisai: Recent Developments and Future Outlook
Table 6.10 GlaxoSmithKline: Key Highlights
Table 6.11 GlaxoSmithKline: Key Characteristics of GSK3745417
Table 6.12 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.13 ImmuneSensor Therapeutics: Key Highlights
Table 6.14 ImmuneSensor Therapeutics: Key Characteristics of IMSA101
Table 6.15 Merck: Key Highlights
Table 6.16 Merck: Key Characteristics of MK-1454 and MK-2118
Table 6.17 Merck: Recent Developments and Future Outlook
Table 6.18 Noxopharm: Key Highlights
Table 6.19 Noxopharm: Key Characteristics of NOX66
Table 6.20 Noxopharm: Recent Developments and Future Outlook
Table 6.21 Spring Bank Pharmaceuticals: Key Highlights
Table 6.22 Spring Bank Pharmaceuticals: Key Characteristics of SB 11285
Table 6.23 Spring Bank Pharmaceuticals: Recent Developments and Future Outlook
Table 6.24 Synlogic: Key Highlights
Table 6.25 Synlogic: Key Characteristics of SYNB1891
Table 6.26 Synlogic: Recent Developments and Future Outlook
Table 6.27 Avammune Therapeutics: Key Highlights
Table 6.28 Curadev Key Highlights
Table 6.29 Nimbus Therapeutics: Key Highlights
Table 6.30 Sirenas: Key Highlights
Table 6.31 STINGINN: Key Highlights
Table 7.1 STING Pathway Targeting Therapeutics: List of Academic Grants, 2015 - Q1 2020
Table 7.2 Grant Analysis: List of Most Attractive Grants
Table 10.1 STING Pathway Targeting Therapeutics: List of Recent Publications, 2019–Q1 2020
Table 11.1 STING Pathway Targeting Therapeutics: List of Partnerships, 2015-Q1 2020
Table 11.2 Most Active Players: Distribution by Number of Partnerships
Table 12.1 STING Pathway Targeting Therapeutics: List of Funding Instances, 2015- Q1 2020
Table 12.2 Funding and Investments: Summary
Table 13.1 Technology Licensing Deals: Milestone Payments
Table 13.2 STING Pathway Targeting TherapeuticsMarket: Average Upfront and Milestone Payments, 2015 - Q1 2020 (USD Million)
Table 16.1 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator
Table 16.2 STING Pathway Targeting Therapeutics: Distribution by Type of Molecule
Table 16.3 STING Pathway Targeting Therapeuticst: Distribution by Type of Modulator and Type of Molecule
Table 16.4 STING Pathway Targeting Therapeutics: Distribution by Phase of Development
Table 16.5 STING Pathway Targeting Therapeutics: Distribution by Phase of Development and Type of Molecule
Table 16.6 STING Pathway Targeting Therapeutic: Distribution by Therapeutic Area
Table 16.7 STING Pathway Targeting Therapeutics: Distribution by Type of Modulator and Leading Indication
Table 16.8 STING Pathway Targeting Therapeutics: Distribution by Type of Therapy
Table 16.9 STING Pathway Targeting Therapeutics: Distribution by Route of Administration
Table 16.10 STING Pathway Targeting Therapeutics: Distribution by Line of Treatment
Table 16.11 STING Pathway Targeting Therapeutics: Distribution of Industry Players by Year of Establishment
Table 16.12 STING Pathway Targeting Therapeutics: Distribution by Company Size
Table 16.13 STING Pathway Targeting Therapeutics: Distribution by Leading Player
Table 16.14 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator
Table 16.15 STING Pathway Targeting Therapeutics: Distribution by Type of Molecule
Table 16.16 STING Pathway Targeting Therapeutics: Analysis by Geography
Table 16.17 Clinical Trials: Distribution by Trial Recruitment Status
Table 16.18 Clinical Trials: Grid Analysis
Table 16.19 Clinical Trials: Distribution by Study Design
Table 16.20 Clinical Trials: Benchmarking of Industry Players by Number of Trials across Key Therapeutics Indications
Table 16.21 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Table 16.22 STING Pathway Targeting Technologies: Distribution by Type of Modulator
Table 16.23 STING Pathway Targeting Technologies: Distribution by Type of Molecule
Table 16.24 STING Pathway Targeting Technologies: Distribution by Year of Establishment
Table 16.25 STING Pathway Targeting Technologies: Distribution by Company Size
Table 16.26 STING Pathway Targeting Technologies: Distribution by Geography
Table 16.27 Aduro Biotech: Net Revenues, FY 2015- Q1 2020 (USD Million)
Table 16.28 Bristol-Myers Squibb: Net Revenues, FY 2015- Q1 2020 (USD Million)
Table 16.29 Eisai: Net Revenues, FY 2015- Q1 2020 (USD Billion)
Table 16.30 GlaxoSmithKline: Net Revenues, FY 2015- Q1 2020 (USD Billion)
Table 16.31 Merck: Net Revenues, FY 2015- Q1 2020 (USD Billion)
Table 16.32 Noxopharm: Net Income FY 2016-Q1 2020 (USD Million)
Table 16.33 Spring Bank Pharmaceuticals: Net Working Capital, FY 2015 – 2019 (USD Million)
Table 16.34 Synlogic: Net Revenues, FY 2016- Q1 2020 (USD Million)
Table 16.35 Academic Grant Analysis: Year –wise Trend of Award
Table 16.36 Academic Grant Analysis: Distribution by Amount Awarded (USD Million)
Table 16.37 Academic Grant Analysis: Distribution by Administering Institute Center
Table 16.38 Academic Grant Analysis: Distribution by Support Period
Table 16.39 Academic Grant Analysis: Distribution by Funding Mechanism
Table 16.40 Academic Grant Analysis: Distribution by Type of Grant Application
Table 16.41 Academic Grant Analysis: Distribution by Activity of Grant
Table 16.42 Academic Grant Analysis: Most Popular NIH Department
Table 16.43 Academic Grant Analysis: Distribution by Recipient Organization
Table 16.44 Academic Grant Analysis: Regional Distribution by Recipient Organization
Table 16.45 Academic Grant Analysis: Distribution by Number of Grants and Amount Invested
Table 16.46 Prominent Project Leaders: Distribution by Number of Grants Awarded
Table 16.47 Prominent Project Leaders: Distribution by Number of Amount Invested
Table 16.48 Academic Grant Analysis: Distribution by Support Period
Table 16.49 Academic Grant Analysis: Distribution by Study Section
Table 16.50 Grant Attractiveness: Relative Attractiveness
Table 16.51 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Table 16.52 Big Pharma Players: Heat Map Analysis of Other Pharmaceutical Companies
Table 16.53 Big Pharma Players: Analysis by Portfolio Diversity
Table 16.54 Big Pharma Players: Analysis by Phase of Development
Table 16.55 Big Pharma Players: Analysis by Type of Molecule
Table 16.56 Big Pharma Players: Analysis by Diversity of Therapeutic Areas
Table 16.57 Big Pharma Players: Analysis by Type of Therapy
Table 16.58 Big Pharma Players: Analysis by Route of Administration
Table 16.59 Spider Web Analysis: AbbVie
Table 16.60 Spider Web Analysis: Bayer
Table 16.61 Spider Web Analysis: Bristol-Myers Squibb
Table 16.62 Spider Web Analysis: Celgene
Table 16.63 Spider Web Analysis: Eisai
Table 16.64 Spider Web Analysis: Eli Lily
Table 16.65 Spider Web Analysis: Genentech
Table 16.66 Spider Web Analysis: GlaxoSmithKline
Table 16.67 Spider Web Analysis: Merck
Table 16.68 Spider Web Analysis: Novartis
Table 16.69 Spider Web Analysis: Novo Nordisk
Table 16.70 Spider Web Analysis: Pfizer
Table 16.71 Spider Web Analysis: Roche
Table 16.72 Spider Web Analysis: Takeda Pharmaceuticals
Table 16.73 Benchmark Analysis of Start-ups: Distribution by Portfolio Diversity
Table 16.74 Benchmark Analysis of Start-ups: Distribution by Phase of Development
Table 16.75 Benchmark Analysis of Start-ups: Distribution by Therapeutic Areas
Table 16.76 Benchmark Analysis of Start-ups: Distribution by Type of Molecule
Table 16.77 Benchmark Analysis of Start-ups: Distribution by Location
Table 16.78 Benchmark Analysis of Start-ups: Distribution by Funding Amount
Table 16.79 Benchmark Analysis of Start-ups: Distribution by Number of Investors
Table 16.80 Benchmark Analysis of Start-ups: Distribution by Progression in Funding
Table 16.81 Benchmark Analysis of Start-ups: Distribution by Partnership Activity
Table 16.82 Benchmark Analysis of Start-ups: Distribution by Patent Portfolio
Table 16.83 Benchmark Analysis of Start-ups: Distribution by Grant Portfolio
Table 16.84 Benchmark Analysis of Start-ups: Distribution by Number of Publications
Table 16.85 Start-up Health Indexing: Roots Analysis Perspective
Table 16.86 Publication Analysis: Cumulative Year-wise Trend, 2015- Q1 2020
Table 16.87 Publication Analysis: Distribution by Type of Publication
Table 16.88 Publication Analysis: Distribution by Type of Publication and Year
Table 16.89 Publication Analysis: Distribution by Study Objective
Table 16.90 Publication Analysis: Distribution by Emerging focus Area
Table 16.91 Publication Analysis: Distribution by Type of STING Modulator
Table 16.92 Publication Analysis: Distribution by Target Pathway
Table 16.93 Publication Analysis: Distribution by Therapeutic Area
Table 16.94 Publication Analysis: Distribution by Therapeutic Area and Type of STING Modulator
Table 16.95 Publication Analysis: Distribution by Type of Publisher
Table 16.96 Most Active Players: Distribution by Number of Publications
Table 16.97 Leading Players: Geographical Distribution by Number of Publications
Table 16.98 Publication Analysis: Distribution by First Author Organization
Table 16.99 Key Journals: Distribution by Number of Publications
Table 16.100 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-Q1 2020
Table 16.101 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.102 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 16.103 Partnerships and Collaborations: Distribution by Type of STING Modulator
Table 16.104 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 16.105 Partnerships and Collaborations: Year-wise Trend by Type of Therapeutic Area
Table 16.106 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Table 16.107 Partnership and Collaborations: Distribution by Technology Platform
Table 16.108 Most Active Players: Distribution by Number of Partnerships
Table 16.109 Most Active Player: Geographical Distribution by Number of Partnerships
Table 16.110 Partnerships and Collaborations: Intercontinental and Intracontinental Distributions
Table 16.111 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2015-Q1 2020
Table 16.112 Funding and Investments: Distribution by Type of STING Modulator and Type of Funding
Table 16.113 Funding and Investments: Cumulative Year-wise Trend, 2015- Q1 2020
Table 16.114 Funding and Investments: Cumulative Amount Invested by Year, 2015- Q1 2020 (USD Million)
Table 16.115 Funding and Investments: Distribution by Type of Funding
Table 16.116 Funding and Investments: Year-wise Trend of Amount Invested, 2015-Q1 2020 (USD Million)
Table 16.117 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 16.118 Funding and Investments: Summary of Investments, 2015-Q1 2020 (USD Million)
Table 16.119 Funding and Investments: Analysis by Type of Modulator
Table 16.120 Funding and Investments: Distribution by Therapeutic Area
Table 16.121 Funding and Investments: Distribution of Amount Invested in Therapeutic Areas, 2015-Q1 2020
Table 16.122 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Table 16.123 Most Active Players: Distribution by Number of Instances
Table 16.124 Most Active Players: Distribution by Amount Raised (USD Million)
Table 16.125 Most Active Investors: Distribution by Amount Raised (USD Million)
Table 16.126 Funding and Investment: Geographical Distribution by Amount Invested (USD Million)
Table 16.127 Funding Instances: Funding and Investment Summary
Table 16.128 Global STING Pathway Targeting Technologies Market: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.129 STING Pathway Targeting Technologies Market for Upfront Payments: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.130 STING Pathway Targeting Technologies Market for Milestone Payments: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.131 STING Pathway Targeting Technologies Market for Agonist: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.132 STING Pathway Targeting Technologies Market for Antagonist: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.133 STING Pathway Targeting Technologies Market for Oncological Disorders: Base, Conservative and Optimistic Scenario, 2020-203 (USD Million)
Table 16.134 STING Pathway Targeting Technologies Market for Inflammatory Disorders: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.135 STING Pathway Targeting Technologies Market for Infectious Diseases: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.136 STING Pathway Targeting Technologies Market for Other Therapeutic Areas: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.137 STING Pathway Targeting Technologies Market for Intratumoral Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.138 STING Pathway Targeting Technologies Market for Intravenous Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.139 STING Pathway Targeting Technologies Market for Oral Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.140 STING Pathway Targeting Technologies Market for Subcutaneous Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.141 STING Pathway Targeting Technologies Market for Other Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.142 STING Pathway Targeting Technologies Market for Non-nucleotides: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.143 STING Pathway Targeting Technologies Market for Cyclic Dinucleotides: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.144 STING Pathway Targeting Technologies Market for Live Biotherapeutics: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.145 STING Pathway Targeting Technologies Market for Oncolytic Viruses: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.146 STING Pathway Targeting Technologies Market for Synthetic Peptides: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.147 STING Pathway Targeting Technologies Market for Other Molecules: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.148 STING Pathway Targeting Technologies Market in North America: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.149 STING Pathway Targeting Technologies Market in Europe: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.150 STING Pathway Targeting Technologies Market in Asia-Pacific: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)

List Of Company

  1. 6 Dimensions Capital
  2. Aalborg University
  3. Aarhus University
  4. AbbVie
  5. Abingworth
  6. Academia Sinica
  7. Actym Therapeutics
  8. Aduro Biotech
  9. Aescap 2.0
  10. AJU IB Investment
  11. Alaska Permanent Fund
  12. Alexandria Venture Investments
  13. All India Institute of Medical Sciences
  14. Allergan
  15. Ally Bridge Group
  16. Almac Diagnostics
  17. Alpine BioVentures
  18. Atlas Venture
  19. Amgen
  20. Anhui University of Science and Technology
  21. Arbutus Biopharma
  22. ARCH Venture Partners
  23. Arctic Aurora LifeScience
  24. Arix Bioscience
  25. Arizona State University
  26. Army Medical University
  27. Arrowpoint Partners
  28. Artimmune
  29. Astellas Pharma
  30. AstraZeneca
  31. Avammune Therapeutics
  32. Baruch S. Blumberg Institute
  33. Bayer
  34. Baylor University Medical Center
  35. Beatson Institute
  36. BellBrook Labs
  37. Beth Israel Deaconess Medical Center
  38. Bicycle Therapeutics
  39. Bill & Melinda Gates Foundation
  40. Biogen
  41. BioInnovation Institute
  42. Institut de Recerca Biomèdica de Lleida (IRBLleida)
  43. BioNovion
  44. Boehringer Ingelheim
  45. Boston Children's Hospital
  46. Boston University
  47. Boxer Capital
  48. Bpifrance
  49. Brigham And Women's Hospital
  50. Bristol-Myers Squibb
  51. BWG Invest
  52. California Institute for Biomedical Research
  53. Cambridge Innovation Capital
  54. The Beatson Institute
  55. Cancer Therapeutics CRC
  56. Canterbury Urology Research Trust
  57. Casdin Capital
  58. Case Western Reserve University
  59. Celgene
  60. Central South University
  61. Center for AIDS Research
  62. CHA University
  63. Chaim Sheba Medical Center
  64. Charité Universitätsmedizin Berlin
  65. Charles River Laboratories
  66. Charles University
  67. Chengwei Capital
  68. China Pharmaceutical University
  69. Chinese Academy of Agricultural Sciences
  70. Chinese Academy of Medical Sciences
  71. Chongqing Medical University
  72. Chulalongkorn University
  73. Cincinnati Childern's Hospital Medical Center
  74. CLI Ventures
  75. Clough Capital Partners
  76. Codiak BioSciences
  77. College of Biotechnology Southwest University
  78. Columbia University Medical Center
  79. CordenPharma
  80. Cristal Therapeutics
  81. CSL
  82. CST Investment Funds
  83. Curadev Pharma
  84. Curative Ventures
  85. Czech Academy of Sciences
  86. Daiichi Sankyo
  87. Dalhousie University
  88. Dana-Farber Cancer Institute
  89. David Geffen School of Medicine
  90. Deaconess Medical Center
  91. Deerfield Management
  92. Dermatology Hospital of Fuzhou
  93. Dezful University of Medical Sciences
  94. DiscoveryBioMed
  95. Duke University Medical Center
  96. Ecole polytechnique fédérale de Lausanne
  97. EcoR1 Capital
  98. Ege University
  99. Eight Roads Ventures
  100. Eisai
  101. Eli Lilly
  102. Emory University School of Medicine
  103. Eulji University School of Medicine
  104. European Institute of Oncology
  105. Evonik Nutrition & Care
  106. Feinstein Institutes for Medical Research
  107. Ferring Pharmaceuticals
  108. Fidelity Biosciences
  109. Flagship Pioneering
  110. Florida State University
  111. Fluorinov Pharma
  112. Fondazione IRCCS Istituto Nazionale dei Tumori
  113. Foresite Capital 
  114. Fox Chase Cancer Center
  115. F-Prime Capital
  116. Franklin Advisers
  117. Frazier Healthcare Partners
  118. Fredrick National Laboratory for Cancer Research
  119. Fudan University
  120. Fujian Medical University
  121. Fund+
  122. Gachon University
  123. Geisel School of Medicine
  124. Genentech
  125. GenesisCare
  126. George Clinical
  127. Georges-Francois Leclerc Cancer Center- UNICNACER
  128. Ghent University Hospital
  129. Gifu University Graduate School of Medicine
  130. Gilead Sciences
  131. Ginkgo Bioworks
  132. GlaxoSmithKline
  133. Green Park & Golf Ventures
  134. Griffith University
  135. Guangzhou Medical University
  136. Guilin Medical University
  137. Gunma University
  138. H3Biomedicine
  139. Hacettepe University
  140. Hackensack University John Theurer Cancer Center
  141. Hallym University
  142. Harbin Veterinary Research Institute
  143. Harvard Medical School
  144. HBM Partners
  145. Health Wildcatters
  146. Helmholtz Centre for Infection Research
  147. Henan Agricultural University
  148. HitGen
  149. Hong Kong University of Science & Technology
  150. Huntsman Cancer Institute
  151. Icahn School of Medicine at Mount Sinai
  152. IFM Therapeutics
  153. ImaBiotech
  154. ImmuneSensor Therapeutics
  155. IMMvention Therapeutix
  156. Inflammatory Bowel Disease Center
  157. Inserm
  158. Institute of Materia Medica
  159. Institute of Radiation Biology
  160. Institut Curie
  161. Gustave Roussy
  162. Institute for Personalized Medicine
  163. Institute of Macromolecular Chemistry ASCR
  164. Institute of Pathogen Biology 
  165. InvivoGen
  166. Invus
  167. Iowa State University
  168. iOx Therapeutics
  169. IQVIA
  170. Istanbul Technical University
  171. Istituto Superiore di Sanità
  172. iTeos Therapeutics
  173. James Graham Brown Cancer Center
  174. Janus Capital Management
  175. Japanese Foundation for Cancer Research
  176. Jazz Pharmaceuticals 
  177. Jennison Associates
  178. Jilin University
  179. Johns Hopkins University School of Medicine
  180. Juntendo University School of Medicine
  181. Kalinga Institute of Industrial Technology
  182. Kangwon National University
  183. Karmanos Cancer Institute
  184. Karol Marcinkowski University of Medical Sciences
  185. Karolinska Institute
  186. Kazia Therapeutics
  187. Keystone Symposia
  188. Kindeva Drug Delivery
  189. Kobe University
  190. Korea Advanced Institute of Science and Technology
  191. KU Leuven
  192. Kuang Tien General Hospital Cancer Center
  193. Kunming University of Science and Technology
  194. RIKEN Center for Integrative Medical Sciences Laboratory for Cell Signaling 
  195. Lerner Research Institute
  196. Les Laboratoires Servier
  197. LIDDS
  198. Life Science Venture Capital Management
  199. Lightstone Ventures
  200. Linköping University
  201. Longwood Fund
  202. Lund University
  203. Magee- Womens Research Institute
  204. Maria Skłodowska-Curie National Research Institute of Oncology
  205. Mary Crowley Cancer Research
  206. Massachusetts General Hospital
  207. Massachusetts Green High Performance Computing Center
  208. Massachusetts Institute of Technology
  209. Max Planck Institute for Immunobiology and Epigenetics
  210. Mayo Clinic
  211. Medical College of Wisconsin
  212. Medigen
  213. Medison Finance
  214. Meharry Medical College
  215. Memorial Sloan Kettering Cancer Center
  216. Merck
  217. Mersana Therapeutics
  218. Michigan State University
  219. Mirna Therapeutics
  220. Moffitt Cancer Center
  221. Monash University
  222. Morningside Group
  223. Mount Sinai Hospital
  224. MPM Capital
  225. MUSC Hollings Cancer Center
  226. Nanchang University
  227. Nanjing Agricultural University
  228. Nanjing Medical University
  229. Nankai Univeristy
  230. Nanobiotix 
  231. National Center of Biomedical Analysis
  232. National Institutes of Biomedical Innovation, Health and Nutrition
  233. National Institutes of Health
  234. National Tsing Hua University
  235. National Yang-Ming University
  236. New Enterprise Associates
  237. New York Medical College
  238. Newcastle University
  239. NEXT Oncology
  240. Nimbus Therapeutics
  241. Ningxia university
  242. Northwest A&F University
  243. Northwestern University
  244. Novartis
  245. Novo Nordisk
  246. Noxopharm
  247. Nyenburgh Holding
  248. Ohio State University College of Medicine
  249. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
  250. Oklahoma State University 
  251. Omega Funds
  252. OncoArendi Therapeutics
  253. Oncology Impact Fund
  254. OnCore Biopharma
  255. OrbiMed HealthCare Fund Management
  256. Oregon Health & Science University
  257. Cormorant Asset Management
  258. Osaka City University
  259. Otsuka Holdings
  260. Otto von Guericke University Magdeburg
  261. Pasteur Institute
  262. Peking University
  263. Penn State College of Medicine
  264. Perceptive Advisors
  265. Pfizer
  266. Portage Biotech
  267. Precision for Medicine
  268. Princeton University
  269. Providence Cancer Institute 
  270. Purdue University
  271. Qatar Investment Authority
  272. Quan Capital
  273. Queen's University
  274. RA Capital Management
  275. Radboudumc
  276. Rambam Health Care Center
  277. Recepta Biopharma
  278. Research Institute of Clinical Medicine
  279. Roche
  280. Rock Springs Capital Management
  281. Rockefeller University
  282. Roivant Sciences
  283. Royal Marsden NHS Foundation Trust
  284. Royal North Shore Hospital
  285. RTW Investments
  286. Rush University Medical Center
  287. Ryvu Therapeutics
  288. Salk Institute for Biological Studies
  289. Sanford Burnham Prebys Medical Discovery Institute
  290. Sanford Cancer Center 
  291. Sanofi
  292. Sapienza University
  293. Schrödinger
  294. Scientipôle
  295. Seoul National Univesity
  296. Sequoia Capital
  297. Severance Hospital
  298. SFPI
  299. Shandong University
  300. Shanghai Jiao Tong University
  301. Shire
  302. Sichuan Agricultural University
  303. Sichuan University
  304. Silicon Therapeutics
  305. Sirenas
  306. Sirona Capital
  307. Smorodintsev Research Institute of Influenza
  308. SMS-oncology
  309. Société Régionale d'Investissement de Wallonie
  310. SOTIO
  311. South China Agricultural University
  312. Southern Medical University
  313. Spring Bank Pharmaceuticals
  314. Springhood Ventures
  315. SR One
  316. St. Jude Children's Research Hospital
  317. Saint Louis University School of Medicine
  318. St. Vincent’s Hospital
  319. Stanford University
  320. Stimunity
  321. STINGINN
  322. Stingray Therapeutics
  323. STipe Therapeutics
  324. Stockholm University
  325. Sun Yat-sen University Cancer Center
  326. Sunstone Life Science Ventures
  327. SV Life Sciences
  328. Swiss Federal Institute of Technology
  329. Sylvester Comprehensive Cancer Center
  330. Synlogic
  331. Takeda Pharmaceutical
  332. Tbilisi State Medical University
  333. Technical University of Munich
  334. Technische Universität Dresden
  335. Tempest Therapeutics
  336. Texas A&M Health Science Center
  337. The Lind Partners
  338. Thomas Jefferson University
  339. Tohoku University
  340. Tongji University
  341. Trillium Therapeutics
  342. Trinity Biomedical Sciences Institute
  343. Tsinghua University
  344. ttopstart
  345. Tufts University 
  346. Tulane University 
  347. TWINCORE-Centre for Experimental and Clinical Infection Research
  348. Umeå University
  349. UND Life Sciences
  350. Universidad Autónoma de Madrid
  351. Universidad Nacional de Río Cuarto
  352. Universidade do Porto
  353. Universidade Federal de Minas Gerais
  354. Université de Lyon
  355. Université libre de Bruxelles
  356. University of Alabama Comprehensive Cancer Center
  357. University of Arizona Cancer Center
  358. University of Bonn
  359. University of Buenos Aries
  360. University of Calgary
  361. University of California
  362. University of Cambridge
  363. University of Chicago
  364. University of Cincinnati
  365. University of Clermont Auvergne
  366. University of Colorado School of Medicine
  367. University of Connecticut School of Medicine
  368. University of Delhi
  369. University of Edinburgh
  370. University of Ferrara
  371. University of Florida
  372. University of Freiburg
  373. University of Glasgow
  374. University of Groningen
  375. University of Hong Kong
  376. University of Illinois College of Medicine
  377. University of Kansas
  378. University of Konstanz
  379. University of Maryland
  380. University of Massachusetts Medical School
  381. University of Miami
  382. University of Michigan 
  383. University of New South Wales
  384. University of North Carolina
  385. University of Orleans
  386. University of Oxford
  387. University of Pennsylvania
  388. University of Piemonte Orientale
  389. University of Pittsburgh
  390. University of Queensland
  391. University of Rhode Island
  392. University of South China
  393. University of South Florida
  394. University of Southern California
  395. University of Texas MD Anderson Cancer Center
  396. University of Texas Southwestern Medical Center
  397. University of Tokyo
  398. University of Toronto
  399. University of Utah 
  400. University of Veterinary Medicine Hannover
  401. University of Virginia
  402. University of Washington
  403. University of Zurich
  404. University of Massachusetts Medical School
  405. UPMC Hillman Cancer Center
  406. Uppsala University
  407. UT Southwestern Medical Center
  408. Vanderbilt University
  409. VENENUM Biodesign
  410. Ventus Therapeutics
  411. Versant Ventures
  412. Vertex Ventures
  413. VIVES Fund
  414. Vyriad
  415. Wake Forest School of Medicine
  416. Washington University School of Medicine
  417. Wayne State University
  418. Weill Cornell Medicine
  419. Weizmann Institute of Science
  420. Wellington Management Company
  421. Wikow Invest
  422. Wuhan University
  423. WuXi AppTec
  424. Xi'an Jiaotong University
  425. Xi'an Medical University
  426. Xuzhou Medical University
  427. Yale Cancer Center
  428. Yangzhou University
  429. Yokohama City University
  430. York University
  431. Zhejiang University School of Medicine
  432. Zhengzhou University

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com